Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Red Cells and Iron
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594003/
https://ncbi.nlm.nih.gov/pubmed/30768680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15790
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars